Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp239 | Anterior and Posterior Pituitary | ECE2019

Peptide receptor radionuclide therapy (PRRT) in patients with giant aggressive pituitary tumors: experience of an Italian referral center and review of literature

Giuffrida Giuseppe , Ferrau Francesco , Laudicella Riccardo , Cotta Oana Ruxandra , Vento Antonio , Baldari Sergio , Cannavo Salvatore

Background: Pituitary tumours (PT) are generally benign, but they can rarely show an aggressive behaviour, invade surrounding structures and/or grow/recur despite multimodal treatment, making their management extremely challenging. According to the latest guidelines, temozolomide (TMZ) can be an option after failure of standard therapies in aggressive PT, while little data are available on alternative approaches such as peptide receptor radionuclide therapy (PRRT). Herein we r...

ea0081ep702 | Pituitary and Neuroendocrinology | ECE2022

Giant pituitary adenomas in children and adolescents: clinical presentation, management and long-term outcome

Giuffrida Giuseppe , giovinazzo salvatore , Alessi Ylenia , Ragonese Marta , Cotta Oana Ruxandra , Angileri Filippo Flavio , Ferrau Francesco , Cannavo Salvatore

Background: Pituitary adenomas in children/adolescents represent around 3% of all intracranial neoplasms. They are more frequently hormone-secreting lesions, usually diagnosed in early childhood and late adolescence. Female gender is generally prevalent, because of most evident symptoms (i.e., irregular periods, galactorrhea, etc.). Giant pituitary adenomas (GA) very rarely occur in pediatric age, posing frequent challenges in their management.Patients a...

ea0037ep1137 | Endocrine tumours | ECE2015

Effects of cyberknife radiotherapy treatment of pituitary adenomas

Puglisi Soraya , Cotta Oana Ruxandra , Conti Alfredo , Pontoriero Antonio , Messina Erika , Albani Adriana , Ferrau Francesco , Ragonese Marta , Torre Maria Luisa , Angileri Flavio , Cannavo Salvatore

Introduction: CyberKnife (CK) is an emerging treatment for pituitary tumours (PT) resistant to other therapies.Patients and methods: We report long-term CK effect on endocrine function and tumour volume in 20 PT patients (11M/10F, mean age 58.6±14.4years). Twelve patients harboured a non functioning adenoma, 2 an ACTH, 5 a GH (one case of TSH co-secretion) and 2 a PRL-secreting PT. Before CK nine patients had normal while 11 presented impaired pitui...